Skip to main content
logo
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
451.40
+7.94 (1.79%)
At close: Nov 28, 2025

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
AMVUTTRA Revenue
1.77B970.45M
Log In
Log In
Log In
Upgrade
ONPATTRO Revenue
197.21M252.86M
Log In
Log In
Log In
Upgrade
GIVLAARI Revenue
286.34M255.87M
Log In
Log In
Log In
Upgrade
OXLUMO Revenue
185.36M167.05M
Log In
Log In
Log In
Upgrade
Total Product Revenue
2.44B1.65B
Log In
Log In
Log In
Upgrade
Roche - Collaboration Revenue
373.94M119.49M
Log In
Log In
Log In
Upgrade
Regeneron Pharmaceuticals - Collaboration Revenue
136.78M302.80M
Log In
Log In
Log In
Upgrade
Novartis AG - Collaboration Revenue
-79.76M
Log In
Log In
Log In
Upgrade
Vir Biotechnology - Collaboration Revenue
--
Log In
Log In
Log In
Upgrade
Other - Collaboration Revenue (Pre-FY2023)
--
Log In
Log In
Log In
Upgrade
Other - Collaboration Revenue (Post-FY2022)
48.65M8.18M
Log In
Log In
Log In
Upgrade
Total Collaboration Revenue
619.37M510.22M
Log In
Log In
Log In
Upgrade
Royalty Revenue
148.04M91.79M
Log In
Log In
Log In
Upgrade
Revenue (Other)
-559.37M-510.22M
Log In
Log In
Log In
Upgrade
Revenue (Total)
3.21B2.25B
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.